Clinical trials
Trials in Malaysia with unknown status
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
293 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2005 | 1 |
| 2006 | 1 |
| 2008 | 3 |
| 2009 | 5 |
| 2010 | 3 |
| 2011 | 8 |
| 2012 | 10 |
| 2013 | 7 |
| 2014 | 10 |
| 2015 | 14 |
| 2016 | 9 |
| 2017 | 15 |
| 2018 | 15 |
| 2019 | 31 |
| 2020 | 37 |
| 2021 | 37 |
| 2022 | 29 |
| 2023 | 42 |
| 2024 | 16 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 293 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| University of Malaya | 76 |
| National University of Malaysia | 27 |
| Universiti Putra Malaysia | 22 |
| Universiti Sains Malaysia | 21 |
| Clinical Research Centre, Malaysia | 11 |
| Ministry of Health, Malaysia | 11 |
| Universiti Kebangsaan Malaysia Medical Centre | 11 |
| Universiti Tunku Abdul Rahman | 6 |
| National University Hospital, Singapore | 5 |
| Penang Hospital, Malaysia | 5 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| COVID-19 | 9 |
| Diabetes Mellitus, Type 2 | 8 |
| Obesity | 7 |
| Coronary Artery Disease | 6 |
| Postoperative Pain | 6 |
| Anemia | 5 |
| Colorectal Neoplasms | 5 |
| Critical Illness | 5 |
| Diabetes Mellitus | 5 |
| Pain | 5 |
Trials
Showing 76 to 100 of 293. Each trial links to its page on Pharma Observatory.
193 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.